Introduction
Approximately 20% of pediatric pre-B ALL evidence the t(1;19)(q23;p13.3) chromosomal translocation (Vogler et al., 1978; Carroll et al., 1984) and accompanying production of E2a-Pbx1 (Kamps et al., 1990; Nourse et al., 1990) . The homeodomains (HDs) of both Pbx1 and E2a-Pbx1 bind TGATT-GAT, and E2a-Pbx1, but not Pbx1, activates transcription through this motif (Lebrun and Cleary, 1994; Lu et al., 1994; van Dijk et al., 1993) . PBX1 prototypes a broadly-expressed gene family including PBX2 and PBX3, and pre-B cells express both PBX2 and PBX3 (Monica et al., 1991) .
All Pbx proteins, as well as E2a-Pbx1, heterodimerize with Hox proteins on TGATTNAT motifs, where N can be A, G, or T (Chan and Mann, 1996; Chang et al., 1996; Knoep¯er et al., 1996; Lu and Kamps, 1997) . The biological signi®cance of cooperative DNA-binding was ®rst suggested by genetic studies in Drosophila and mice. In Drosophila, the Pbx1 homologue, Extradenticle, is capable of regulating normal dierentiation, in part, by activating or repressing gene expression in concert with HD proteins encoded by homeotic complex (HOM-C) genes (Bejsovec and Wieschaus, 1993; Rauskolb et al., 1993) . Aberrant expression of HOM-C genes produces homeotic transformations of structures along the anterior-posterior axis of the Drosophila larva and ectopic expression of Hox genes, the eucaryotic homologues of HOM-C genes, produces homeotic transformations in mice (Charite et al., 1994; Chisaka and Capecchi, 1991) .
E2a-Pbx1 exhibits multiple transforming activities, causing myeloblastic (Kamps and Baltimore, 1993) and T-lymphoblastic leukemias in mice (Dedera et al., 1993) , blocking dierentiation of primary myeloblasts in marrow cultures without altering their factor-dependence , and producing foci in NIH3T3 ®broblasts (Kamps et al., 1991) . In the same assays, Pbx1 has no transforming potential, and disruption of the transactivation function of E2a abolishes all forms of transformation by E2a-Pbx1, suggesting that E2a-Pbx1 transforms by activating gene transcription. Interestingly, while wild-type DNA-binding potential by the Pbx1 homeodomain is important for blocking myeloid dierentiation , it is not required for focus-formation in NIH3T3 cells or for induction of T-cell ALL (Dedera et al., 1993; Kamps et al., 1996) , suggesting that E2a-Pbx1 possess two distinct transforming activities, a DNA-binding dependent activity that disrupts dierentiation and a DNAbinding independent activity that stimulates growth. In NIH3T3 cells, E2a-Pbx1 activates expression of genes that are normally expressed in other cell types such as brain, liver, and testis (Fu and Kamps, 1997; McWhirter et al., 1997) . These E2a-Pbx1 target genes are not expressed in myeloid cell lines immortalized by E2a-Pbx1 indicating that E2a-Pbx1 activates gene transcription in conjunction with other cell type-speci®c transcription factors (Fu and Kamps, 1997) .
One approach to understanding the role of E2a-Pbx1 in human pre-B cell leukemogenesis is identifying genes whose expression invariantly accompanies the t(1;19) translocation, and determining both their mechanism of transcriptional activation and the function of the proteins they encode. From a therapeutic standpoint, antigens associated with speci®c subgroups of leukemias are potential targets for intervention, surface antigens representing targets for immunologic approaches, and intracellular enzymes representing targets for chemical suicide' inhibitors. The fact that E2a-Pbx1 activates aberrant gene expression in mouse ®broblasts suggested it might do likewise in human pre-B cells, and the de novo production of such proteins exclusively in this leukemic subset would make them therapeutic targets. We considered two approaches to identify genes consistently upregulated by E2a-Pbx1 in t(1;19) ALL's. The ®rst was identifying genes activated when E2a-Pbx1 is expressed in a human pre-B ALL cell line that lacked the t(1;19) translocation and asking whether these same genes were activated in t(1;19)'s. While this approach has the advantage of identifying genes upregulated by E2a-Pbx1, it would fail to identify genes whose activation by E2a-Pbx1 required a complimenting mutation, such as coactivation of a gene encoding a transcriptional partner. Coactivation of Meis1 and HoxA9 in mouse myeloid leukemia provides one example of cooperating oncogenes that encode transcription factors that bind each other and may need to heterodimerize as part of their oncogenic mechanism (Nakamura et al., 1996) . Considering the possibility that E2a-Pbx1 might also require a second cooperating oncogene expressed only in t(1;19) cells and that E2a-Pbx1 induces apoptosis when expressed in non-t(1;19) pre-B ALL cell lines (Smith et al., 1997) , we choose to attempt to identify genes that are uniquely transcribed in the t(1;19) subset of pre-B ALL. Among the genes discovered, EB-1 was transcriptionally activated exclusively and invariantly both in pre-B cell lines and in pre-B ALL marrow aspirates containing the t(1;19). EB-1 is normally expressed in brain and testis, and encodes a putative signaling molecule containing a phosphotyrosine binding domain and tandem SAM domains homologous to those of the Eph tyrosine kinase receptor C-terminal tail. Invariant aberrant expression of EB-1 demonstrates that novel antigens are produced speci®cally in the t(1;19)-positive subset of pre-B ALL and may be useful as therapeutic targets. The EB-1 protein could contribute to the transformed phenotype of pre-B ALL by interfering with signals that regulate normal growth and dierentiation within the B cell lineage.
Results
Identi®cation of 5 genes transcribed predominantly or exclusively in pre-B ALLs containing the t(1;19) translocation Representation display analysis (RDA) PCR was used to identify mRNA's speci®cally expressed in the t(1;19)-containing human pre-B ALL cell line 697 that were not expressed in Nalm-6, which does not contain the t(1;19) translocation. PCR products corresponding to dierentially-expressed mRNA's were subcloned into pBluescript and used as probes to determine expression levels in seven pre-B cell lines containing the t(1;19) translocation (referred to as t(1;19) lines; lanes 5 ± 11 in Figure 1a ; Table 1 ) and in four pre-B cell lines that do not contain the t(1;19) translocation (referred to as non-t(1;19) lines; lanes 1 ± 4 in Figure 1a ; Table 1 ). To control for the possibility that t(1;19)-speci®c gene expression actually resulted from the normal expression of a stage-speci®c pre-B cell gene that is expressed in t(1;19)'s due to their dierentiation state rather than their speci®c content of E2a-Pbx1, the expression of stage-speci®c markers (cytosolic immunoglobulin, CD antigens, HLA-DR) was also quanti®ed for a subset of lines (Table 1) . Cell lines yielded similar pro®les of antigen expression, and speci®c dierences, such as the level of CD10 expression, were not con®ned to either the t(1;19) or the non-t(1;19) subsets.
Among 21 mRNA's that were expressed at signi®cantly higher levels in 697 cells than in Nalm-6 cells, ®ve corresponded to genes transcriptionally upregulated in at least ®ve of seven t(1;19) lines and were either undetectable or expressed at lower levels in four non-t(1;19) lines. Three of the ®ve transcripts were encoded by the previously-identi®ed genes T-Plastin, Aldehyde Dehydrogenase-1 (ADH-1), and Caldesmon, while the remaining two transcripts did not match any sequences in the GenBank database, and their genes were designated EB-1 and EB-2 (E2a-Pbx1 activated gene in pre-B cells 1 and 2). The 549 nucleotide EB-1 RDA PCR fragment contained a single open reading frame encoding 182 residues, while the 394 EB-2 RDA PCR fragment contained no open reading frame greater than 20 residues. The Caldesmon, EB-1, and EB-2 genes were upregulated in all seven t(1;19) cell lines ( Figure 1a ). Caldesmon and EB-2 were also expressed in one of the seven non-t(1;19)'s ± Nalm-6 and Kopn35, respectively ± while EB-1 was not expressed in any of the non-t(1;19) lines. T-plastin and ALDH-1 were expressed exclusively in the t(1;19) lines but only in ®ve of seven, and their coexpression was not linked (Figure 1a) . The heterogeneous pattern of mRNA's bound by both the EB-1 and EB-2 probes was not due to nonspeci®c binding to multiple cellular RNA's because neither probe bound signi®cantly to RNA's from non t(1;19) lines, even when ten-times as much poly(A) + was analysed (lanes 12 and 13 in Figure 1a ). In the case of EB-1, nonoverlapping cDNA probes bound precisely the same population of transcripts, con®rming speci®c binding to heterogeneous transcripts. Subsequent sequence analysis of EB-1 cDNA clones from a 697 cell library demonstrated the presence of incompletely-and dierentially-spliced mRNA's. As further proof that single gene products accounted for the heterogenous populations of mRNA's bound by EB-1 or EB-2, we performed RT ± PCR using radiolabeled EB-1 or EB-2 primers and mRNA from each pre-B ALL cell line as template. If the transcripts detected in certain t(1;19) lines represented cross-hybridization of the EB-1 probe to related gene products, RNA from these lines would fail to amplify by this RT ± PCR protocol. Speci®c DNA fragments of the predicted size were ampli®ed in all seven t(1;19)s by each primer set and, as predicted by the Northern blot, the EB-2 transcript was also upregulated in the non t(1;19) cell line, Kopn35. The EB-1 transcript was upregulated exclusively in t(1;19) cell lines ( Figure 1b) .
Expression of ADH1, Caldesmon, T-Plastin, EB-1, and EB-2 were also examined in mature B-cells (BJAB), T-cells (HSB2 and Jurkat), promyelocytic cells (HL-60), monocytic cells (U937), the erythroblastic cells (HEL). T-plastin and EB-1 were not expressed in any of these lines, EB-2 was expressed at barely detectable levels in BJAB and HSB-2, caldesmon at very low levels in BJAB, HSB-2, and HEL, and ADH1 at moderately abundant levels in BJAB and HEL (data Figure 1 Expression of Caldesmon, T-Plastin, ALDH-1, EB-1 and EB-2 in pre-B ALL cells containing or lacking the t(1;19) chromosomal translocation. (a) Northern blot analysis of total cellular RNA derived from four cell lines lacking the t(1;19) translocation (Kopn-32, Kopn-35, Nalm-6, and Reh; lanes 1 ± 4 respectively) and in seven cell lines containing the t(1;19) translocation (Kopn-36, Kopn-54, Kopn-63, Rch, Pre-Alp, 697 and Sup-B27; lanes 5 ± 11, respectively). Lanes 12 and 13; analysis of 6 mg polyadenylated mRNA from Nalm-6 and 697 cells, respectively. Transcript size is indicated at right. (b) RT ± PCR ampli®cation of EB-1 and EB-2 DNA fragments using 32 P-labeled oligonucleotides. cDNA from 100 ng of total RNA was used as template for ampli®cation of EB-1, EB-1-S1, EB-1-S2, EB-2, and G3DPH. Thirty-®ve thermocycles of ampli®cation were conducted for EB-1, EB-1-S1 and EB-1-S2, and 25 cycles for EB-2 and G3DPH. (c) RT ± PCR detection of EB-1 transcripts in total RNA from patient marrow using 32 P-labeled primers. cDNA derived from reverse transcription of RNA from bone marrow aspirates was used as template. Lanes 1 ± 5; RNA templates derived from pre-B ALL aspirates not containing the t(1;19), as deduced by PCR across the E2a-Pbx1 junction, lanes 6 ± 8; RNA templates derived from pre-B ALL aspirates evidencing the t(1;19) as deduced by PCR across the E2a-Pbx1 junction. Reverse transcribed RNA from Reh cells was used as a negative control (7) and the EB-1 cDNA was used as a positive control (+). Identical amounts of reverse-transcribed RNA were used for ampli®cation with actinspeci®c oligonucleotides to control for relative template abundance. Forty cycles of ampli®cation was conducted for EB-1 and 22 cycles for actin. Radiolabeled oligonucleotides were identical to those used in (b) ++ signi®es 50 ± 100% control; +signi®es 10 ± 50% control; 7signi®es less than 10% control.
d Detailed analysis of Nalm-6 and Rch surface markers unavailable not shown). Because EB-1 was upregulated exclusively and invariantly in pre-B ALL containing the t(1;19), we focused our eorts on characterizing this transcript.
EB-1 is transcriptionally activated in marrow samples from patients containing the t(1;19) translocation
Genes uniquely transcribed in t(1;19) cells lines could represent targets of oncoprotein E2a-Pbx1, genes whose function compliments that of E2a-Pbx1 in the genesis of pre-B ALL, or genes transcriptionally activated during establishment of the t(1;19) cell lines that are positively selected by coexpression of E2a-Pbx1. To determine whether transcription of EB-1 was activated before cells were established as lines, RT ± PCR using 32 P-labeled EB-1-speci®c DNA primers were used to amplify EB-1 transcripts from RNA isolated from total marrow cells of eight patients with pediatric pre-B ALL, three bearing the t(1;19) translocation, and ®ve lacking the t(1;19). After 40 cycles of PCR, EB-1 was undetectable or barely detectable in total RNA from the ®ve marrow samples whose leukemic cells lacked the t(1;19) translocation ( Figure 1c , lanes 1 ± 5), while those containing the t(1;19) produced strong signals (lanes 6 ± 8). This analysis demonstrated that EB-1 expression occurs in vivo prior to establishment of t(1;19) cells as cell lines and indicated that EB-1 was not expressed signi®cantly in other marrow cell types.
The relative abundance of EB-1 transcripts was measured by PCR in cell lines and marrow samples using 32 P-labeled PCR primers, quantitating 32 P-labeled EB-1-speci®c RT ± PCR product at a point in the linear range of its ampli®cation (35 cycles), dividing by the signal arising from an RT ± PCR reaction using beta actin-speci®c primers and a cycle number within its linear range of ampli®cation (18 cycles) and comparing the ratio for t(1;19) and non-t(1;19) pre-B ALL cell lines (see Materials and methods). The three marrow samples containing t(1;19) leukemia contained 110 ± 430-times as much EB-1 transcript as the average detectable values of their t(1;19)-negative counterparts whereas the seven t(1;19) cell lines contained 55 ± 489-times as much EB-1 transcripts as the average detectable values of their t(1;19)-negative counterparts. Both beta-actin and G3DPH were used as PCR controls for quantitating upregulation of EB-1 mRNA in the human pre-B cell lines, and yielded comparable results. Three t(1;19)-negative patient samples and two t(1;19)-negative cell lines had undetectable EB-1 signal; thus, by comparison to these samples, upregulation of EB-1 in t(1;19) samples is even greater than 110 ± 430-fold. This analysis demonstrated that EB-1 is signi®cantly upregulated in t(1;19)-positive cells and that its magnitude of upregulation does not change during establishment of the t(1;19) leukemias as cell lines.
EB-1 and EB-2 exhibit tissue-speci®c and early-embryonic expression
Because Pbx1 may be involved in regulating cell and tissue development and dierentiation, and because transformation of mouse ®broblasts by E2a-Pbx1 is accompanied by transcriptional activation of tissuespeci®c and developmentally-regulated genes, we analysed the expression pattern of Caldesmon, TPlastin, ALDH-1, EB-1, and EB-2 in both adult and fetal tissues. Caldesmon, T-Plastin and ALDH-1 are expressed in all adult tissues, through their expression levels dier greatly (Figure 2) , and EB-2 is expressed at barely detectable constant levels in most tissues, including spleen (data not shown). Intriguingly, EB-1 was expressed detectably only in testis and brain, the same cell types that express the highest levels of PBX1. In fetal tissue both EB-1 and EB-2 were expressed in much higher levels in brain than in lung, liver, or kidney, again consistent with their potential transcriptional regulation by Pbx1 (Figure 3) . Caldesmon, T-plastin, and ALDH-1, by contrast, exhibited abundant expression in fetal lung, liver and kidney, and varying expression in fetal brain. EB-1 encodes a protein with a`PTB' type of phosphotyrosine-binding domain and with two SAM domains homologous to those in the C-terminal domain of Eph-related tyrosine kinases A cDNA library was made using 697 cell mRNA and screened with the original EB-1 PCR DNA fragment. Five unique overlapping cDNA's containing the sequence of the EB-1 PCR fragment were identi®ed. The composite clone encoded 754 residues comprising an internal portion of the EB-1 protein. 3' rapid ampli®cation of cDNA ends (RACE) was used to identify sequences encoding the full-length C-terminus, and two consecutive rounds of 5' RACE yielded sequences encoding an additional 165 residues of Nterminal sequence. The composite sequence does not appear to represent a full length cDNA because the reading frame remained open to the 5' end, and the ®rst methionine codon, located 270 nucleotides into the coding sequence, did not represent an optimal site for translation initiation. Despite screening cDNA libraries from both human brain and from 697 cells with EB-1 probes, as well as by 5' RACE, a full-length EB-1 cDNA clearly encoding a full-length N-terminus was not identi®ed. The 918 amino acids encoded by the composite EB-1 sequence were colinear with and 36% identical to that encoded by a partial cDNA from a gene designated`similar-to-human ankyrin' (SimAk-1), identi®ed by screening a cDNA library from the human immature myeloid cell line KG-1 for new transcripts (Figure 4) . The partial protein sequence of SimAk-1 encodes 1181 amino acids whose N-terminal region contains six ankyrin-like repeats, whose middle region contains two tandem sterile alpha motif (SAM) domains that are well conserved with those residing Cterminal to the tyrosine kinase domain of all Eph family receptor tyrosine kinases, and whose C-terminal region contains a phosphotyrosine binding (PTB) domain that is widely conserved among the signaling proteins such as Shc and dNumb ( Figure 5 ). EB-1 lacks the ankyrin repeats, and is homologous to SimAk-1 in its SAM and PTB domains.
Residues 478 to the C-terminus of EB-1 were represented in their entirety by 18 overlapping human expressed sequence tags (hEST) derived from brain, testis, and lung cDNA libraries. Preceding residue 478 of EB-1, three unique EST clones all encoded MMWQCHVSAQDYRYYPVDGYSLLKR-FPLHPLTG as the full-length N-terminus ( Figure  4b ). No 697 cell cDNA's encoded the N-terminus predicted by the EST sequences; rather, three independent clones (clone 1, 3 and 8 of Figure 4a ) encoded the same novel 5' sequences. The EB-1 Nterminal domain spanning L1 to R477 was not contained in any hEST. To determine whether the unique 5' sequences in EB-1 were present in all t(1;19) cells lines, RT ± PCR was performed using one ampli®cation primer complimentary to the common 3' sequences, and a second or third primer identical to dierent 5' EB-1-speci®c sequences. These pairs of primers ampli®ed fragments designated EB-1-S1 and EB-1-S2 whose abundance was 25 ± 75-times greater (EB-1-S1 fragment) or 100 ± 420-times greater (EB-1-S1) in t(1;19)-containing cell lines. Non-t(1;19) cell lines expressed low levels of this form of EB-1. Thus, the pre-B cell form of the EB-1 transcript is upregulated at least 25-fold in cells containing the t(1;19) translocation.
The heterogeneous pattern of EB1 mRNA observed on Northern blots was due, at least in part, to both incomplete splicing and dierential splicing. Clones 3 and 6 both encoded alternative C-termini (designated in Figure 4 ), while clone 2 (not represented in drawings) encoded a C-terminus identical to clone 8. At their 5' ends, clone 3 contained an Alu repeat sequence, and clone 2, a LINE repeat indicating a high frequency of incomplete splicing.
The two SAM domains in EB-1 were 64% and 60% identical to those of SimAk-1 and 36% and 33% identical to that of Eph ( Figure 5 ). Each SAM domain of EB-1 retained most of the invariant residues found in all Eph tyrosine kinase receptors (W488, L489, D521, G526 and I536 in the Nterminal domain; W562, L563, F575 and I609 in the C-terminal domain). The SAM domains of both SimAk-1 and EB-1 did, however, diverge from those of the Eph family at ®ve highly conserved residues; L501, R533, E593, K599 and R606, indicating that the function or speci®city of these domains in SimAk-1 and EB-1 has diverged somewhat from that of Eph family proteins. cDNA clones 3 and 6 diverged near the C-terminal end of their tandem SAM domains, at residues 597 and 633, respectively, encoding 17 and 32 additional residues before encountering a stop codon (Figure 4 ). These protein sequences also bore no signi®cant homology with other proteins in GenBank, and it is unclear whether they arise from alternative exon usage or by translation of unprocessed introns.
EB-1 and SimAk-1 contained the highest degree of sequence identity in their PTB domains, over 82% (Figure 5b ). When compared with the sequence of other PTB domains, EB-1 was 26% identical to that of dNumb, a protein involved in cell fate determination and asymmetric cell division in neuronal cell development and 24.5% identical to that of Shc, a signal transduction adapter molecule that is itself transforming when overexpressed. EB-1 retained glycine at position 849 which corresponds to G192 of dNumb and G195 of hShc and has been suggested to juxtapose phosphotyrosine. S804 and G738 are widely conserved in PTB domains as well as in EB-1 and two other residues in the dNumb PTB domain predicted to contact phosphotyrosine (R171, V191) are replaced by conservative changes in EB-1 (H827 and L848).
Discussion
One approach to understanding how E2a-Pbx1 functions biochemically as well as how it causes leukemia is to identify E2a-Pbx1 target genes in pre-B ALL cells, determine how their promoters are activated by E2a-Pbx1, and determine the ability of the proteins they encode to alter cell growth or dierentiation. Designing such an approach for E2a-Pbx1 target genes that mediate pre-B cell leukemia is complicated by two factors. First, while oncoproteins such as Ras signal to conserved subsets of genes in divergent cell types, E2a-Pbx1 alters gene transcription in a cell-type-speci®c manner, activating transcription of genes in mouse NIH3T3 ®broblasts that remain silent in mouse myeloblasts immortalized by E2a-Pbx1. Thus, while many cell types might be appropriate for identi®cation of genes mediating transformation by Ras, human pre-B cells must be used to identify how E2a-Pbx1 alters gene expression in pre-B cell leukemia. The second concern is that E2a-Pbx1 may cooperate with other transcription factors to alter gene expression in pre-B ALL, and therefore expressing E2a-Pbx1 in control pre-B ALL cell lines lacking the t(1;19) may not result in the expression of the relevant E2a-Pbx1 target genes normally expressed in t(1;19)-containing pre-B ALL. In light of evidence supporting coactivation of the Meis1 and HoxA9 transcription factors in myeloid leukemia (Nakamura et al, 1996) , as well as evidence that E2a-Pbx1 induces apoptosis in pre-B ALL lines lacking the t(1;19) and cooperates with Pim1 in the production of T-cell ALL (Smith et al., 1997; Feldman et al., 1997) , we initiated studies to identify potentially relevant E2a-Pbx1 target genes by identifying of genes consistently activated in t(1;19) leukemias that are not expressed in pre-B ALL cell lines that lack the t(1;19). This approach can identify E2a-Pbx1 target genes whose transcription requires coactivation of genes encoding E2a-Pbx1 heterodimer partners as well as genes whose transcriptional activation is independent of the presence of E2a-Pbx1 and whose products perform an independent complimenting function in altering gene transcription, cellular proliferation, or dierentiation.
Genes expressed invariantly in t(1;19) pre-B ALL lines and marrow samples included EB-1, EB-2 and Caldesmon. Strikingly, EB-1 transcripts were expressed exactly where Pbx1 is most highly expressed, in brain and in testis (Roberts et al., 1995) , suggesting that its normal expression could be regulated by Pbx proteins and its aberrant expression by E2a-Pbx1 in pre-B ALL through a mechanism in which E2a-Pbx1 replaces endogenous Pbx proteins bound to enhancer elements. Transient expression of E2a-Pbx1 in Nalm-6 pre-B cells, however, which lack the t(1;19) did not induce detectable EB-1 expression (by RT PCT), suggesting that transcriptional activation of EB-1 may require either the function of a cooperating oncogene or the normal expression of genes within the exact t(1;19) target cell, which are not expressed by other pre-B ALL's blocked at slightly dierent stages of molecular dierentiation.
Because ALDH-1 and T-Plastin were transcriptionally upregulated in only ®ve of seven t(1;19)-containing pre-B ALL cell lines, and because caldesmon was upregulated in one of four non-t(1;19) cell lines in addition to all seven t(1;19) cell lines, the possibility that each of these genes is a E2a-Pbx1 target gene remains uncertain. Both T-Plastin and Caldesmon are actin bundling proteins, and expression of such cytoskeletal proteins have been widely reported to be correlated with oncogenic phenotypes (Green et al., 1990; Davies et al., 1993; De Silva et al., 1994) . Tplastin, one of three plastin isoforms, is upregulated up to 12-fold in cisplatin-resistant tumor cells by comparison to their parental non-resistant cells, and the expression of antisense T-plastin RNA restores cisplatin sensitivity (Hisano et al., 1996) . Caldesmon confers morphological changes on ®broblasts when overexpressed (Surgucheva and Bryan, 1995) . ALDH-1 is responsible for catalyzing the NAD + -dependent, irreversible conversion of aldehydes to carboxylic acids, its expression corresponds to a drug resistant phenotype, and overexpression of ALDH-1 leads to signi®cant increases in cyclophosphamide resistance in the human and murine hematopoietic cell lines U937 and L1210 (Magni et al., 1996) . The frequent, yet sporadic, upregulation of ALDH-1 and T-plastin indicates that even if they are targets of E2a-Pbx1, transcriptionally activated in conjunction with a second mutation that occurs in a subset of t(1;19)'s, they are unlikely to represent essential mediators of leukemogenesis by E2a-Pbx1. Caldesmon, however, may be a direct and important target of E2a-Pbx1 that is also transcriptionally activated by other mechanisms in a subset of non-t(1;19) pre-B cell leukemias.
EB-1 contained three domains homologous to those used in tyrosine kinase signal transduction, two SAM domains and a PTB domain. SAM domains can selfassociate or bind other signaling proteins (Schultz et al., 1997) . In yeast, growth arrest during sexual dierentiation requires signaling from STE4 to the MAP kinase homologue Byr2p, through interaction of their SAM domains (Barr et al., 1996) . SAM domains are also positioned C-terminal to the catalytic domains of most Eph-family tyrosine kinase receptors, which orchestrate axonal guidance and bundling (Sefton and Nieto, 1997) . Activation of the ELK tyrosine kinase receptor by LERK-2/Fc induces phosphorylation within the SAM domain at Tyr-928 which promotes binding of the Greb-10 through its SH2 domain (Stein et al., 1996) . Tyr-928 of ELK is a conserved SAM domain residue present in both SAM domains of EB-1 (Y497 and Y571). While the majority of Eph-related kinases are expressed in brain, certain members of the Eph family containing SAM domains are expressed predominantly in epithelial cells (ERK; Kiyokawa et al., 1994) , in erythroid progenitors (HTK; Inada et al., 1997) , and in pre-B and pre-T cells (HEK; Wicks et al., 1992) . Expression of HEK in pre-B cells indicates that pre-B cells are likely to contain factors that bind SAM domains. A SAM domain is also found in diacylglycerol kinase delta (DGKd; Sakane et al., 1996) , a protein that controls cellular proliferation (Sakane and Kanoh, 1997) . Because cellular SAM domain binding proteins are thought to regulate the function of proteins mediating proliferation (DGKd) or differentiation (Eph members), overexpression of EB-1 could sequester these factors and disregulate the normal proliferation or dierentiation control in pre-B cells.
C-terminal to the SAM domain, EB-1 contained a PTB domain related to those of the Numb family of Drosophila neuronal cell fate-determining factors and to those of the mammalian Shc signal adapter proteins. PTB domains are distinct from SH2 domains, which also bind phosphotyrosine, in that their speci®city is derived from residues N-terminal to the phosphotyrosine (van der Geer and Pawson, 1995) . PTB domains have proven roles in regulating cell proliferation and dierentiation. In Drosophila, signaling through the transmembrane protein Notch is important for neurogenesis and the PTB domain of dNumb, by its asymmetrical distribution into progeny cells, determines the fate of daughter cells, possibly by interfering with the Notch signal pathway (CamposOrtega, 1996) by direct binding to the Notch intracellular domain (Guo et al., 1996) . Because EB-1 contains a PTB domain most similar to that of Numb, which is preceded by a stretch of 25 residues homologous to those of Numb proteins but divergent from those of Shc (residues 700 ± 725), EB-1 could also suppress or deregulate signals that regulate normal proliferation or dierentiation of B cell progenitors. Alternatively, the PTB could target EB-1 to the location of speci®c tyrosine-phosphorylated ligands and the Eph homology domains could either bind and stimulate or sequester interacting factors, thus altering signal transduction pathways controlling proliferation or dierentiation. In this regard, it is interesting to note that overexpression of Crk, an avian oncoprotein containing two SH2 domains and an SH3 domain transforms NIH3T3 ®broblasts, binds tyrosine-phosphorylated membrane proteins via its SH2 domains, and induces both anchorage-independent growth and activation of Jun kinase via interaction of its SH3 domain with the guanine nucleotide exchange protein, C3G (Tanaka et al., 1997) .
Recently, De Lau et al. (1998) identi®ed the granulocyte colony stimulating factor receptor gene (G-CSFR) as induced in a non-t(1;19) cell line coincident with activation of E2a-Pbx1 expression and as consistently upregulated in t(1;19)-containing leukemias. We did not identify cDNA fragments encoding G-CSFR, potentially due to its low expression level, to negative selection by our RDA protocol, or to the selective ampli®cation of other more abundant sequences representing dierences between Nalm-6 (t(1;19)-negative) and 697 (t(1;19)-positive) pre-B cells.
Manic fringe (MFNG) is another example of oncogenic transcription factor-speci®c target gene. MFNG is a morphogenetic gene normally involved in somatic development that is transcriptionally activated in NIH3T3 cells expressing EWS/FLI1 and is strongly expressed in Ewing's sarcoma containing the EWS/FLI1 chromosomal translocation. Overexpression of MFNG in NIH3T3 cells renders them tumorigenic (May et al., 1997) . EAT-2, a novel protein containing the SH2 type of phosphotyrosinebinding domain, is also induced by EWS/FLI1 in NIH3T3 ®broblasts (Thompson et al., 1996) . In other examples, oncogenic transcription factors have been found to activate transcription of more broadly expressed genes, such as the platelet-derived growth factor receptor alpha by EWS-WT1 in desmoplastic small round cell tumors (Lee et al., 1997) , and Bcl-2 by AML1/ETO in myeloid leukemias (Klampfer et al., 1996) . It will be important to obtain full-length EB-1 cDNA's in order to determine its potential function on cellular proliferation, dierentiation, and apoptosis.
Materials and methods

Cell lines and cell culture
Kopn32, Kopn35, Kopn36, Kopn54 and Kopn63 cell lines were established at Yamanashi Medical University in Japan. The t(1;19)-containing cell lines Rch, pre-Alp, and Sup-B27 were kindly provided by Dr Stephen Smith of University of Chicago. All leukemia cell lines were cultured in RPMI 1640 supplemented with 10% fetal bovine serum and 50 mM 2-mercaptoethanol.
Representational dierence analysis
Representational dierence analysis (RDA) PCR was used to clone cDNA's speci®cally expressed in the t(1;19)-positive human pre-B ALL cell line 697 that were not expressed in Nalm-6 pre-B cells (Lisitsyn et al, 1993; Hubank and Schatz, 1994) . cDNA was synthesized from 3 mg of mrNA isolated from Nalm-6 and 697 cells and digested with DpnII. Adapters composed of two oligonucleotides ± 5'-AGCACTCTCCA-GCCTCTCACCGCA-3' (RBgl 24) and 5'-GATCTGCGGT-GA-3' (RBgl 12) were ligated to the blunt cDNA. This mixture was ampli®ed by PCR using RBgl 24, and the adapters were excised with DpnII. A second pair of adapters, 5'-ACCGACGTCGACTATCCATGAACA-3' (JBgl 24) and 5'-GATCTGTTCATG-3' (JBgl 12), were ligated to the ampli®ed fragments from the 697 cell cDNA and hybridized with the ampli®ed cDNA fragments from the Nalm-6 control (RBgl adapters removed) at a ratio of 1:100 for 24 h. The hybridization mix was used as template for ampli®cation by PCR using JBgl 24 primers. A second round of subtraction was performed by removing the JBgl adapters from an aliquot of the ®rst round PCR, ligating a third pair of annealed oligonucleotides adapters: 5'-AGGCAACTGTGC-TATCCGAGGGAA-3' (NBgl 24) and 5'-GATCTTCCC-TCG-3' (NBgl 12), hybridizing with driver amplcons at a ratio of 1:800 and amplifying with NBgl 24 primers.
Northern blotting analysis
Total RNA was extracted from cultured cells using acidic phenol (Chomczynski and Sacchi, 1987) . Twenty mgs RNA was loaded per lane on a 1% agarose gel containing formaldehyde. After electrophoresis, RNA was transferred to a nylon membrane (Magna Graf, MSI) and immobilized by UV cross-linking.
32 P-labeled DNA probes were synthesized by extension of random hexamers, using denatured DNA according to the manufacturers speci®cations (Pharmacia Biotech). The QuikHyb system was used for annealing the radioactive probe to immobilized RNA according to the manufacturers speci®cations (Strategene).
Library screening and cloning
Custom LamdaTriplEX cDNA library of 697 leukemia cell line (Clontech) was screened using the EB-1 RDA PCR probe according to the manufacturer's protocol. Positive Lamda TripleEx clones were converted to pTriplEx phagemid by in vivo excision when introduced into a bacterial host expressing cre recombinase.
RT ± PCR
Total RNA extracted from pre-B, cytoplasmic Ig+ bone marrow was a gift from Dr James Downing of St Jude Children's Research Hospital. Total RNA from cell lines was extracted as described in Northern blotting analysis. Total RNA was subjected to reverse transcription, using Moloney Murine Leukemia virus reverse transcriptase and oligo-dT. The 32
